BIOCON PHARMA LIMITED

Regeneron filed a new patent infringement complaint against Amgen on June 17, 2025, asserting U.S. Patent No. 12,331,099 covering a stable liquid ophthalmic formulation without buffer requirements.

Biocon has received regulatory approval from India's Central Drugs Standard Control Organisation (CDSCO) for its diabetes drug liraglutide, marking a significant milestone for the company's pharmaceutical portfolio.

Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.

Biocon chairperson Kiran Mazumdar-Shaw announced plans for a ₹4,500 crore qualified institutional placement to convert structured venture debt into equity, aiming to strengthen the company's balance sheet.

• Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to biologics expansion in Malaysia and $50 million to generics. • The biopharmaceutical company reported a 153% surge in Q4 net profit to Rs 344 crore, driven by strong growth in generics and steady progress in biosimilars. • Biocon is expanding its product portfolio with recent launches of lenalidomide and dasatinib in the US, liraglutide in the UK, and plans to launch bevacizumab and insulin aspart in the US market.

Biocon Group reported strong Q4FY25 performance with revenue reaching Rs 4,454 crore, up 15% year-on-year, driven by significant market share gains in biosimilars and new product launches.

Biocon launched a ₹4,500 crore Qualified Institutional Placement with a floor price of ₹340.20 per share to strengthen its financial position.

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received FDA approval for Norepinephrine Bitartrate Injection USP, used to raise blood pressure in adults with acute hypotension.

Brazilian pharmaceutical giant Hypera plans to introduce a generic version of semaglutide in the domestic market next year, positioning itself in the growing diabetes and weight-loss treatment sector.

Danish pharmaceutical giant Novo Nordisk confirms readiness to launch its blockbuster GLP-1 drug Semaglutide (Ozempic) in India despite patent expiration in January 2026, emphasizing continued market leadership strategy.